|
|
Blood, 1 February 2007, Vol. 109, No. 3, pp. 1322-1330.
Prepublished online as a Blood First Edition Paper on October 12, 2006; DOI 10.1182/blood-2006-04-020172.
 Previous Article | Table of Contents | Next Article 
TRANSPLANTATION
Comparative single-institute analysis of cord blood transplantation from unrelated donors with bone marrow or peripheral blood stem-cell transplants from related donors in adult patients with hematologic malignancies after myeloablative conditioning regimen
Satoshi Takahashi1,
Jun Ooi1,
Akira Tomonari1,
Takaaki Konuma1,
Nobuhiro Tsukada1,
Maki Oiwa-Monna1,
Kenji Fukuno1,
Michihiro Uchiyama1,
Kashiya Takasugi1,
Tohru Iseki1,
Arinobu Tojo1,
Takuhiro Yamaguchi2, and
Shigetaka Asano1,3
1 Division of Molecular Therapy, The Advanced Clinical Research Center, The Institute of Medical Science, The University of Tokyo, Japan;
2 Department of Biostatistics/Epidemiology and Preventive Health Sciences, School of Health Sciences and Nursing, University of Tokyo, Japan;
3 School of Science and Engineering, Waseda University, Tokyo, Japan
We studied the clinical outcomes of 171 adults with hematologic malignancies who received unrelated cord blood transplantation (CBT) as a primary unrelated stem-cell source (n = 100), or bone marrow transplant (BMT) or peripheral blood stem-cell transplant (PBSCT) from related donors (n = 71, 55 BMT and 16 PBSCT). All patients received myeloablative regimens including 12 Gy total body irradiation. We analyzed the hematologic recovery, and risks of graft-versus-host disease (GVHD), transplantation-related mortality (TRM) and relapse, and disease-free survival (DFS) using Cox proportional hazards models. Significant delays in engraftment occurred after cord blood transplantation; however, overall engraftment rates were almost the same for both grafts. The cumulative incidences of grades III to IV acute and extensive-type chronic GVHDs among CBT recipients were significantly lower than those among BMT/PBSCT recipients. Multivariate analysis demonstrated no apparent differences in TRM (9% in CBT and 13% in BMT/PBSCT recipients), relapse (17% in CBT and 26% in BMT/PBSCT recipients), and DFS (70% in CBT and 60% in BMT/PBSCT recipients) between both groups. These data suggest that unrelated cord blood could be as safe and effective a stem-cell source as related bone marrow or mobilized peripheral blood for adult patients when it is used as a primary unrelated stem-cell source.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
K. KOBAYASHI, Y. MAEDA, Y. HARA, M. NISHIE-KATAOKA, H. NISHIMORI, H. SUGIYAMA, N. NAMBA, S. KUBONISHI, M. NIIYA, K. SHINAGAWA, et al.
Clinical Outcomes of Unrelated Donor Umbilical Cord Blood Transplantation for 30 Adults with Hematological Malignancies
Anticancer Res,
May 1, 2009;
29(5):
1763 - 1770.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Gluckman and V. Rocha
Cord blood transplantation: state of the art
Haematologica,
April 1, 2009;
94(4):
451 - 454.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Atsuta, R. Suzuki, T. Nagamura-Inoue, S. Taniguchi, S. Takahashi, S. Kai, H. Sakamaki, Y. Kouzai, M. Kasai, T. Fukuda, et al.
Disease-specific analyses of unrelated cord blood transplantation compared with unrelated bone marrow transplantation in adult patients with acute leukemia
Blood,
February 19, 2009;
113(8):
1631 - 1638.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. N. Barker
Umbilical Cord Blood (UCB) Transplantation: An Alternative to the Use of Unrelated Volunteer Donors?
Hematology,
January 1, 2007;
2007(1):
55 - 61.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. M. Lazarus and S. Luger
Which Patients with Adult Acute Lymphoblastic Leukemia Should Undergo a Hematopoietic Stem Cell Transplantation? Case-Based Discussion
Hematology,
January 1, 2007;
2007(1):
444 - 452.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
